http://newsroom.accesspharma.com Breaking News, stock info, SEC filings, multimedia and other information on Access Pharmaceuticals, Inc. Thu, 11 Mar 2010 21:06:18 +0000 http://backend.userland.com/rss092 en Cobalamin Seen as Broadly Applicable for Oral Delivery of Many Large Molecule Drugs Now Administered by Injection Dallas, TX, March 11, 2010 ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies.  The studies, which confirm earlier findings, were ... http://newsroom.accesspharma.com/access-pharmaceuticals-reports-significant-oral-bioavailability-of-cobalamintm-oral-insulin-in-additional-studies/ Dallas, TX, February 2, 2010 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today announced that it closed its previously announced sale of approximately 2.10 million shares of its common stock and warrants to purchase approximately 1.05 million shares of its common stock for gross proceeds of approximately $6.3 million onJanuary 22, 2010. ... http://newsroom.accesspharma.com/access-pharmaceuticals-announces-closing-of-6-3-million-in-registered-direct-offering/ Dallas, TX January 22, 2010 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today announced that it has entered into definitive agreements with accredited investors to sell in a registered direct offering an aggregate of 2.10 million shares of its common stock at a price of$3.00 per share for aggregate gross ... http://newsroom.accesspharma.com/access-pharmaceuticals-raises-6-3-million-in-registered-direct-offering/ DALLAS, TX, January 19, 2010 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) provided an update today on its Cobalamin™ oral drug delivery product development programs. The proprietary Cobalamin™ technology utilizes the body's natural vitamin B12 oral uptake mechanism to facilitate oral absorption of pharmaceuticals by a "Trojan horse" mechanism. Access has focused ... http://newsroom.accesspharma.com/access-pharmaceuticals-cobalamin-oral-insulin-achieves-greater-than-80-oral-bioavailability-in-preclinical-models/ Update on worldwide development on ProLindac DALLAS, TX, January 7 2009 ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two ... http://newsroom.accesspharma.com/access-pharmaceuticals-announces-completion-of-prolindac-monotherapy-trial-and-initiation-of-combination-study/ Dallas, TX, January 6, 2010 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) today announced President and CEO Jeffrey B. Davis will provide an update on Access' product and clinical development plans for 2010 during a presentation at the OneMedPlace's Forum 2010, Emerging Company Finance Conference, on Wednesday, January 13, 2010, at 3:00 p.m. Pacific ... http://newsroom.accesspharma.com/access-pharmaceuticals-to-present-at-onemedplace-forum-2010/ Critical step toward U.S.. marketing launch of MuGard DALLAS, TX, December 15, 2009 ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), today announced the appointment of Frank Jacobucci to the position of Vice President, Sales and Marketing.  Mr. Jacobucci will be primarily responsible for the Company’s marketing launch of MuGard, an FDA approved treatment for ... http://newsroom.accesspharma.com/access-pharmaceuticals-appoints-sales-and-marketing-executive/ Health care professional and patient feedback very positive DALLAS, TX, December 3, 2009 ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy. MuGard is commercially launched by Access’ partner, ... http://newsroom.accesspharma.com/access-pharmaceuticals-provides-update-on-mugard-commercial-launch-in-europe/ DALLAS, TX., November 17, 2009 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) today announced that a recommendation report was issued by ChangeWave, a research network that identifies emerging trends and companies best-positioned to capitalize in today’s marketplace. The report was written by Mr. Joshua Levine, Editor of ChangeWave Investing and ChangeWave ... http://newsroom.accesspharma.com/changewave-issues-buy-recommendation-on-access-pharmaceuticals/ European Launch Ongoing-- Initial Clinician And Patient Feedback Very Positive DALLAS, TX, November 11, 2009 ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), today provided an update on its North American commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.  Access intends to commercially ... http://newsroom.accesspharma.com/access-pharmaceuticals-provides-update-on-mugard-commercial-launch-in-north-america/